In Poon et al’s recent paper entitled “Identification of Process
Localized mRNAs from Cultured Hippocampal Neurons” they note that several
of the messages, which they identified as components of dendritically
localized staufen-containing RNA granules i.e. G-protein alpha-inhibiting
2 (Gnalphai2), neuronatin (NNAT), eukaryotic initiation factor 5 (eIF5),
Rho-interacting protein 3 (RIP3) and cytoplasmic dynein light chain have
also been identified as FMRP target mRNAs (Brown et al., 2001; Miyashiro
et al., 2003). However, they failed to mention that we showed that eEF-1A
mRNA (one of the prototypical messages in their paper) binds to FMRP in
vitro and that heterologous expression of FMRP in cultured cells results
in a concentration-dependent decrease in eEF-1A protein, but has no effect
on the levels of its mRNA (Sung et al., 2003). This effect is not
observed when FXR1P is heterologously expressed. Furthermore,
lymphoblastoid cells from fragile X patients have 3-fold more eEF-1A
protein than lymphoblastoid cells from normal controls, despite the fact
that eEF-1A mRNA levels in these two cell types are the same. Thus, eEF-
1A mRNA has the hallmarks of a message whose translation is negatively
regulated by FMRP.
These data coupled with recently published studies on eEF-1A
translation in the brain have potential implications for understanding the
function of FMRP in dendrites. Both eEF-1A and FMRP are transiently
increased following treatment with the group I mGluR agonist DHPG (Huang
et al., 2005; Hou et al., 2006). This suggests that newly synthesized
FMRP is not able to negatively regulate eEF-1A mRNA in dendrites. This
might occur if FMRP were either not phosphorylated and thus unable to
stall the translation of eEF-1A mRNA (Ceman et al., 2003), or if the FMRP
isoform that was locally synthesized lacked the phosphorylation site via
alternative splicing. Alternatively, perhaps in dendrites FMRP is bound
to a protein that modifies its translational regulatory activity, turning
it from a negative to a positive translational regulator. Further
experiments will be necessary to differentiate these possibilities and
characterize the underlying mechanism of eEF-1A local translation.
Robert B. Denman, Ph.D.
Head Biochemical Molecular Neurobiology Laboratory
New York State Institute for Basic Research
In Developmental Disabilities
1050 Forest Hill Road
Staten Island, NY 10314
Tel: 718-494-5199
Fax: 718-494-5905
e-mail: rbdenman@yahoo.com
References
Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin
X, Feng Y, Wilkinson KD, Keene JD (2001) Microarray identification of FMRP
-associated brain mRNAs and altered mRNA translational profiles in fragile
X syndrome. Cell 107:477-487.
Ceman S, O'Donnell WT, Reed M, Patton S, Pohl J, Warren ST (2003)
Phosphorylation influences the translation state of FMRP-associated
polyribosomes. Hum Mol Genet 12:3295-3305.
Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006) Dynamic
translational and proteasomal regulation of fragile X mental retardation
protein controls mGluR-dependent Long-Term Depression. Neuron 51:441-454.
Huang F, Chotiner JK, Steward O (2005) The mRNA for elongation factor
1{alpha} is localized in dendrites and translated in response to
treatments that induce long-term depression. J Neurosci 25:7199-7209.
Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu
L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J (2003) RNA cargoes
associating with FMRP reveal deficits in cellular functioning in Fmr1 null
mice. Neuron 37:417-431.
Sung Y-J, Dolzhanskaya N, Nolin SL, Brown WT, Currie JR, Denman RB
(2003) The fragile X mental retardation protein FMRP binds elongation
factor 1A mRNA and negatively regulates its translation in vivo. J Biol
Chem 278:15669-15678.